Examining cognitive disorders in hereditary spastic paraplegia type 4
Cognitive Disorders and Metabolism in 18-FDG- PET in Hereditary Spastic Paraplegia Type 4 (SPG4)
This study is trying to see how hereditary spastic paraplegia type 4 affects thinking and memory by looking at brain scans and comparing them with tests and genetic information from people with the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Nancy) |
| Trial ID | NCT06260982 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize cognitive impairments associated with hereditary spastic paraplegia type 4 using 18-FDG-PET metabolic imaging. The primary objective is to identify specific patterns of cognitive dysfunction in affected individuals. Additionally, the study will explore correlations between neuropsychological assessments, clinical evaluations, imaging data, and genetic information. By understanding these relationships, the research seeks to provide a clearer picture of the cognitive aspects of this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with a pathogenic variant in the SPAST gene living in the Grand Est region of France.
Not a fit: Patients with dementia or cognitive disorders unrelated to hereditary spastic paraplegia type 4 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of cognitive disorders in patients with hereditary spastic paraplegia type 4, leading to better diagnosis and management strategies.
How similar studies have performed: While cognitive disorders in hereditary spastic paraplegia have been noted, this specific approach using 18-FDG-PET imaging is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age, living in the Grand Est region (France) * Patient with a pathogenic or probably pathogenic variant (class 4 or 5) in the SPAST gene. Exclusion Criteria: * dementia comorbidities or cognitive disorders unrelated to the pathology that may affect neuropsychological tests.
Where this trial is running
Nancy
- Centre hospitalier régional universitaire — Nancy, France (Recruiting)
Study contacts
- Principal investigator: Mathilde Renaud — Central Hospital Nancy
- Study coordinator: Mathilde Renaud
- Email: m.renaud2@chru-nancy.fr
- Phone: +333 83 85 17 80
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.